
Quarterly report 2025-Q2
added 07-30-2025
Merit Medical Systems EBITDA 2011-2026 | MMSI
Earnings before Interest, Taxes, Depreciation, and Amortization (EBITDA), is an often used measure of a company's profitability. Financial analysts use EBITDA for a number of purposes including calculating simple valuations of a firm, estimating cash flows, and assessing debt servicing capability. The uses for EBITDA in financial analysis are numerous, but in practice should be more restrained. While EBITDA has some useful applications, it should be used with caution, as the problems with EBITDA are abundant and can lead to a number of misguided conclusions.[1]
EBITDA is an important indicator for investors and analysts because it allows them to evaluate a company's operating profit without considering the impact of financial expenses, taxes, or non-cash depreciation and amortization. It provides better comparability between companies in different industries or with different tax conditions.
EBITDA is often used to assess a company's ability to generate cash flow and repay debts. It can also serve as a measure of a company's operational efficiency, as it shows how profitable the core business is, regardless of external factors such as interest or taxes.
However, it is important to note that EBITDA is not an official financial statement measure and can be defined and calculated differently by companies. Therefore, investors and analysts should exercise caution when using EBITDA as an evaluation tool and combine it with other financial metrics and information to get a more complete picture of a company's financial condition.
Annual EBITDA Merit Medical Systems
| 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 258 M | 214 M | 169 M | 145 M | 92.5 M | 144 M | 129 M | 99.3 M | 79.2 M | 76 M | 76.6 M | 64.4 M | 54.6 M | 58.2 M |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 258 M | 54.6 M | 119 M |
Quarterly EBITDA Merit Medical Systems
| 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 77.9 M | 70.3 M | - | 54.2 M | 70 M | 59.5 M | - | 50.5 M | 42.2 M | 46.9 M | - | 30.8 M | 35.4 M | 35.7 M | - | 79.1 M | 21.3 M | 35.6 M | 16 M | 70.5 M | 28 M | 24.7 M | -3.41 M | 65.6 M | 57.2 M | 31.9 M | 13.7 M | 71.5 M | 47.9 M | 24.1 M | 13.2 M | 40.3 M | 39.1 M | 18.4 M | 12.6 M | 34.6 M | 31.3 M | 17.4 M | - | 36.3 M | 30.5 M | 17.8 M | - | 38.8 M | 25 M | 15.2 M | - | 32.3 M | 22.5 M | 9.44 M | - | 25.8 M | 18.5 M | 12.8 M | - | 20.8 M | 20.3 M | 15 M |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 79.1 M | -3.41 M | 34.8 M |
References
- Brockman, C. M., & Russell, J. W. (2012). EBITDA: use it... or lose it?. International Journal of Business, Accounting and Finance, 6(2), 84-93.
EBITDA of other stocks in the Medical instruments industry
| Issuer | EBITDA | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Atrion Corporation
ATRI
|
37.7 K | - | - | $ 810 M | ||
|
Baxter International
BAX
|
1.01 B | $ 19.11 | -0.98 % | $ 9.75 B | ||
|
Becton, Dickinson and Company
BDX
|
5.04 B | $ 194.07 | -0.8 % | $ 55.8 B | ||
|
Luminex Corporation
LMNX
|
72.9 M | - | - | $ 1.75 B | ||
|
Akers Biosciences, Inc.
AKER
|
-12.3 M | - | -9.52 % | $ 20.6 M | ||
|
Ekso Bionics Holdings
EKSO
|
-8.85 M | $ 8.64 | -18.34 % | $ 174 M | ||
|
Antares Pharma, Inc.
ATRS
|
16.2 M | - | - | $ 955 M | ||
|
Cantel Medical Corp.
CMD
|
123 M | - | -1.18 % | $ 3.4 B | ||
|
CRH Medical Corporation
CRHM
|
33.9 M | - | - | $ 282 M | ||
|
Hill-Rom Holdings, Inc.
HRC
|
518 M | - | -0.05 % | $ 10.3 B | ||
|
Harvard Bioscience
HBIO
|
3.37 M | $ 0.67 | 1.66 % | $ 28.4 M | ||
|
Varian Medical Systems, Inc.
VAR
|
60 M | - | -0.02 % | $ 16.3 B | ||
|
Alcon
ALC
|
580 M | $ 78.81 | -0.64 % | $ 40.4 B | ||
|
Repro Med Systems
KRMD
|
-9.4 M | $ 5.81 | 2.11 % | $ 265 M | ||
|
AtriCure
ATRC
|
-28.8 M | $ 39.56 | -1.54 % | $ 1.86 B | ||
|
ICU Medical
ICUI
|
262 M | $ 142.67 | -1.36 % | $ 3.48 B | ||
|
electroCore
ECOR
|
-18.3 M | $ 4.49 | -3.55 % | $ 24.8 K | ||
|
iRhythm Technologies
IRTC
|
-94.8 M | $ 177.44 | -0.63 % | $ 5.54 B | ||
|
AngioDynamics
ANGO
|
-14.2 M | $ 12.84 | -1.23 % | $ 525 M | ||
|
Isoray
ISR
|
-88.6 M | - | 0.03 % | $ 108 M | ||
|
The Cooper Companies
COO
|
1.06 B | $ 81.96 | -0.62 % | $ 16.3 B | ||
|
Glaukos Corporation
GKOS
|
-95 M | $ 112.91 | -1.16 % | $ 5.47 B | ||
|
LeMaitre Vascular
LMAT
|
61.9 M | $ 81.1 | -2.3 % | $ 1.82 B | ||
|
Haemonetics Corporation
HAE
|
337 M | $ 80.15 | -1.02 % | $ 4.03 B | ||
|
InfuSystem Holdings
INFU
|
15 M | $ 8.97 | 0.67 % | $ 185 M | ||
|
Nephros
NEPH
|
-1.38 M | $ 4.88 | 3.39 % | $ 50.7 M | ||
|
Masimo Corporation
MASI
|
-164 M | $ 130.06 | -0.77 % | $ 6.93 B | ||
|
Intuitive Surgical
ISRG
|
2.79 B | $ 566.36 | -1.09 % | $ 201 B | ||
|
OraSure Technologies
OSUR
|
-17.4 M | $ 2.42 | -2.02 % | $ 180 M | ||
|
Microbot Medical
MBOT
|
-9.75 M | $ 2.0 | -2.44 % | $ 20.4 M | ||
|
Milestone Scientific
MLSS
|
-6.72 M | $ 0.27 | -0.22 % | $ 21.5 M | ||
|
NeuroMetrix
NURO
|
-8.69 M | - | 5.05 % | $ 9.02 M | ||
|
Envista Holdings Corporation
NVST
|
-915 M | $ 21.71 | -0.91 % | $ 3.74 B | ||
|
Pro-Dex
PDEX
|
11.9 M | $ 38.48 | -0.3 % | $ 127 M | ||
|
Predictive Oncology
POAI
|
-10.8 M | - | - | $ 32.4 M | ||
|
Pulse Biosciences
PLSE
|
-43 M | $ 13.73 | 0.22 % | $ 660 M | ||
|
ResMed
RMD
|
1.16 B | $ 240.87 | -0.91 % | $ 35.2 B | ||
|
Repligen Corporation
RGEN
|
116 M | $ 163.86 | -1.64 % | $ 9.13 M | ||
|
BioLife Solutions
BLFS
|
-1.97 M | $ 24.18 | -1.95 % | $ 1.11 B | ||
|
STERIS plc
STE
|
1.34 B | $ 253.52 | -0.76 % | $ 25 B | ||
|
Stereotaxis
STXS
|
-21.2 M | $ 2.3 | -0.22 % | $ 186 M | ||
|
Retractable Technologies
RVP
|
-13.5 M | $ 0.77 | -0.63 % | $ 23.1 M | ||
|
STAAR Surgical Company
STAA
|
-5.72 M | $ 23.09 | -0.52 % | $ 1.13 B | ||
|
Utah Medical Products
UTMD
|
17.4 M | $ 55.96 | -0.57 % | $ 203 M | ||
|
Teleflex Incorporated
TFX
|
426 M | $ 122.04 | 0.35 % | $ 5.72 B | ||
|
DENTSPLY SIRONA
XRAY
|
-530 M | $ 11.43 | 0.35 % | $ 2.32 B | ||
|
West Pharmaceutical Services
WST
|
725 M | $ 275.14 | -0.62 % | $ 20.1 B |